STOCK TITAN

[8-K] Eaton Corporation, plc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 4 overview: On 22 Jul 2025, Maiken Keson-Brookes, Chief Legal Officer & Secretary of Mural Oncology plc (MURA), sold 2,572 ordinary shares at a weighted-average price of $2.48 (price band $2.46-$2.51). The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on 20 Sep 2024.

Following the transaction, the insider directly owns 68,834 shares, which include 62,203 unvested RSUs. No derivative securities were reported and no other insiders participated. The filing indicates direct ownership status and contains the standard acknowledgements and signatures required under Section 16.

Panoramica del Modulo 4: Il 22 luglio 2025, Maiken Keson-Brookes, Chief Legal Officer e Segretario di Mural Oncology plc (MURA), ha venduto 2.572 azioni ordinarie ad un prezzo medio ponderato di 2,48 $ (intervallo di prezzo 2,46-2,51 $). La vendita è stata effettuata in base a un piano di trading Rule 10b5-1 adottato il 20 settembre 2024.

A seguito della transazione, l'insider possiede direttamente 68.834 azioni, che includono 62.203 RSU non maturate. Non sono stati riportati titoli derivati e nessun altro insider ha partecipato. La dichiarazione indica lo stato di proprietà diretta e contiene le consuete dichiarazioni e firme richieste ai sensi della Sezione 16.

Resumen del Formulario 4: El 22 de julio de 2025, Maiken Keson-Brookes, Directora Legal y Secretaria de Mural Oncology plc (MURA), vendió 2,572 acciones ordinarias a un precio promedio ponderado de $2.48 (rango de precio $2.46-$2.51). La venta se realizó conforme a un plan de negociación bajo la Regla 10b5-1 adoptado el 20 de septiembre de 2024.

Tras la transacción, el insider posee directamente 68,834 acciones, que incluyen 62,203 RSU no adquiridas. No se reportaron valores derivados ni participaron otros insiders. La presentación indica el estado de propiedad directa y contiene los reconocimientos y firmas estándar requeridos bajo la Sección 16.

Form 4 개요: 2025년 7월 22일, Mural Oncology plc(MURA)의 최고 법률 책임자 겸 비서인 Maiken Keson-Brookes가 2,572 보통주를 매도했으며, 가중평균 가격은 $2.48 (가격 범위 $2.46-$2.51)이었습니다. 이 매도는 2024년 9월 20일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다.

거래 후 내부자는 직접 68,834주를 보유하고 있으며, 이 중 62,203주의 미확정 RSU가 포함되어 있습니다. 파생 증권은 보고되지 않았고 다른 내부자의 참여도 없었습니다. 제출 서류는 직접 소유 상태를 나타내며, 섹션 16에 따른 표준 확인 및 서명이 포함되어 있습니다.

Résumé du formulaire 4 : Le 22 juillet 2025, Maiken Keson-Brookes, Directrice juridique et Secrétaire de Mural Oncology plc (MURA), a vendu 2 572 actions ordinaires à un prix moyen pondéré de 2,48 $ (fourchette de prix 2,46-2,51 $). La vente a été réalisée conformément à un plan de négociation Rule 10b5-1 adopté le 20 septembre 2024.

Suite à cette transaction, l'initié possède directement 68 834 actions, incluant 62 203 RSU non acquises. Aucun titre dérivé n'a été déclaré et aucun autre initié n'a participé. Le dépôt indique un statut de propriété directe et contient les reconnaissances et signatures standard requises en vertu de la Section 16.

Überblick über Formular 4: Am 22. Juli 2025 verkaufte Maiken Keson-Brookes, Chief Legal Officer und Sekretärin von Mural Oncology plc (MURA), 2.572 Stammaktien zu einem gewichteten Durchschnittspreis von 2,48 $ (Preisspanne 2,46-2,51 $). Der Verkauf erfolgte gemäß einem am 20. September 2024 angenommenen Rule 10b5-1 Handelsplan.

Nach der Transaktion besitzt der Insider direkt 68.834 Aktien, darunter 62.203 nicht unverfallbare RSUs. Es wurden keine derivativen Wertpapiere gemeldet und keine weiteren Insider waren beteiligt. Die Einreichung weist den Status des direkten Eigentums aus und enthält die standardmäßigen Bestätigungen und Unterschriften gemäß Abschnitt 16.

Positive
  • Sale conducted under a pre-arranged Rule 10b5-1 plan, reducing perception of opportunistic trading
  • Insider retains 68,834 shares (incl. 62,203 RSUs), indicating continued equity stake
Negative
  • Insider selling 2,572 shares may be interpreted by some investors as a mild negative sentiment

Insights

TL;DR: Small 10b5-1 sale; negligible impact on ownership, neutral signal.

The disposal represents roughly 3.7 % of Keson-Brookes’ reported holdings (68,834 post-sale). Because it was executed under a pre-established 10b5-1 plan, the transaction is generally viewed as routine and reduces signalling risk. The insider still retains a substantial position, including a large block of unvested RSUs, implying continued alignment with shareholder interests. No options, warrants, or other derivatives were exercised or disposed. Given the limited size and pre-planned nature, market impact should be minimal.

Panoramica del Modulo 4: Il 22 luglio 2025, Maiken Keson-Brookes, Chief Legal Officer e Segretario di Mural Oncology plc (MURA), ha venduto 2.572 azioni ordinarie ad un prezzo medio ponderato di 2,48 $ (intervallo di prezzo 2,46-2,51 $). La vendita è stata effettuata in base a un piano di trading Rule 10b5-1 adottato il 20 settembre 2024.

A seguito della transazione, l'insider possiede direttamente 68.834 azioni, che includono 62.203 RSU non maturate. Non sono stati riportati titoli derivati e nessun altro insider ha partecipato. La dichiarazione indica lo stato di proprietà diretta e contiene le consuete dichiarazioni e firme richieste ai sensi della Sezione 16.

Resumen del Formulario 4: El 22 de julio de 2025, Maiken Keson-Brookes, Directora Legal y Secretaria de Mural Oncology plc (MURA), vendió 2,572 acciones ordinarias a un precio promedio ponderado de $2.48 (rango de precio $2.46-$2.51). La venta se realizó conforme a un plan de negociación bajo la Regla 10b5-1 adoptado el 20 de septiembre de 2024.

Tras la transacción, el insider posee directamente 68,834 acciones, que incluyen 62,203 RSU no adquiridas. No se reportaron valores derivados ni participaron otros insiders. La presentación indica el estado de propiedad directa y contiene los reconocimientos y firmas estándar requeridos bajo la Sección 16.

Form 4 개요: 2025년 7월 22일, Mural Oncology plc(MURA)의 최고 법률 책임자 겸 비서인 Maiken Keson-Brookes가 2,572 보통주를 매도했으며, 가중평균 가격은 $2.48 (가격 범위 $2.46-$2.51)이었습니다. 이 매도는 2024년 9월 20일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다.

거래 후 내부자는 직접 68,834주를 보유하고 있으며, 이 중 62,203주의 미확정 RSU가 포함되어 있습니다. 파생 증권은 보고되지 않았고 다른 내부자의 참여도 없었습니다. 제출 서류는 직접 소유 상태를 나타내며, 섹션 16에 따른 표준 확인 및 서명이 포함되어 있습니다.

Résumé du formulaire 4 : Le 22 juillet 2025, Maiken Keson-Brookes, Directrice juridique et Secrétaire de Mural Oncology plc (MURA), a vendu 2 572 actions ordinaires à un prix moyen pondéré de 2,48 $ (fourchette de prix 2,46-2,51 $). La vente a été réalisée conformément à un plan de négociation Rule 10b5-1 adopté le 20 septembre 2024.

Suite à cette transaction, l'initié possède directement 68 834 actions, incluant 62 203 RSU non acquises. Aucun titre dérivé n'a été déclaré et aucun autre initié n'a participé. Le dépôt indique un statut de propriété directe et contient les reconnaissances et signatures standard requises en vertu de la Section 16.

Überblick über Formular 4: Am 22. Juli 2025 verkaufte Maiken Keson-Brookes, Chief Legal Officer und Sekretärin von Mural Oncology plc (MURA), 2.572 Stammaktien zu einem gewichteten Durchschnittspreis von 2,48 $ (Preisspanne 2,46-2,51 $). Der Verkauf erfolgte gemäß einem am 20. September 2024 angenommenen Rule 10b5-1 Handelsplan.

Nach der Transaktion besitzt der Insider direkt 68.834 Aktien, darunter 62.203 nicht unverfallbare RSUs. Es wurden keine derivativen Wertpapiere gemeldet und keine weiteren Insider waren beteiligt. Die Einreichung weist den Status des direkten Eigentums aus und enthält die standardmäßigen Bestätigungen und Unterschriften gemäß Abschnitt 16.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 23, 2025
 
EATON CORPORATION plc

(Exact name of registrant as specified in its charter)
 
Ireland
 
000-54863
 
98-1059235
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

 Eaton House, 30 Pembroke Road, Dublin 4, Ireland
  D04 Y0C2
(Address of principal executive offices)
 
(Zip Code)

 
+353 1637 2900
 
 
(Registrant’s telephone number, including area code)
 

 
Not applicable
 
 
(Former name or former address, if changed since last report.)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Ordinary shares ($0.01 par value)
 
ETN
 
New York Stock Exchange
4.450% Senior Notes due 2030
 
ETN/30
 
New York Stock Exchange
3.625% Senior Notes due 2035
 
ETN/35
 
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 23, 2025, the Board of Directors (the “Board”) of Eaton Corporation plc (the “Company”) increased its size from eleven to twelve members and elected Gerald Johnson to fill the resulting vacancy, effective immediately.  Mr. Johnson, 62, is the retired Executive Vice President, Global Manufacturing and Sustainability of General Motors Company, the global automobile manufacturer.  Mr. Johnson was appointed to serve on the Audit Committee and the Governance Committee of the Board.

Mr. Johnson will receive compensation pursuant to the Company’s standard arrangements for non-employee directors as described in its Proxy Statement for the 2025 Annual General Meeting of Shareholders, which was filed with the Securities and Exchange Commission (“SEC”) on March 14, 2025.  In connection with his election to the Board, Mr. Johnson will receive a Restricted Stock Unit (“RSU”) grant on August 7, 2025 representing a pro rata portion of the 2025 RSU award granted to all other non-employee directors on May 6, 2025.  His RSU grant will be the equivalent of $127,500 in Ordinary Shares, based on the 30-day average closing price of such shares leading up to the grant date.  This amount represents 75% of the full $170,000 2025 RSU award amount, reflecting the portion of the 2025 grant cycle that he will serve on the Board.

Both the Company and its wholly owned subsidiary, Eaton Corporation, have entered into standard indemnification agreements for the Company’s directors with Mr. Johnson, the forms of which were filed with the SEC on February 28, 2013 as Exhibits 10(bb) and 10(cc) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

There are no related party transactions involving Mr. Johnson that would require disclosure pursuant to Item 404(a) of Regulation S-K.  There are no arrangements or understandings between Mr. Johnson and any other persons pursuant to which he was selected as a director of the Company.

A copy of the press release issued by the Company on July 23, 2025 announcing Mr. Johnson’s election is attached as Exhibit 99.1 to this Report and incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
Exhibit Description
99.1
Press Release of Eaton Corporation plc dated July 23, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Eaton Corporation plc
   
Date: July 23, 2025
/s/ Lucy Clark Dougherty
 
Lucy Clark Dougherty
Executive Vice President and Chief Legal Officer

 

FAQ

How many MURA shares did the officer sell?

The Form 4 reports a sale of 2,572 ordinary shares on 22 Jul 2025.

At what price were the shares sold?

Shares were sold at a weighted-average price of $2.48, with individual trades between $2.46 and $2.51.

Does the officer still hold MURA shares after the sale?

Yes. Post-transaction, the officer directly owns 68,834 shares, including 62,203 unvested RSUs.

Was the sale part of a 10b5-1 trading plan?

Yes. The filing states the transaction was executed under a Rule 10b5-1 plan adopted 20 Sep 2024.

Were any derivative securities involved?

No derivative securities were acquired or disposed of in this filing.

Who is the reporting person in this Form 4?

Maiken Keson-Brookes, Chief Legal Officer and Secretary of Mural Oncology plc.
Eaton

NYSE:ETN

ETN Rankings

ETN Latest News

ETN Latest SEC Filings

ETN Stock Data

145.82B
390.52M
0.2%
85.99%
1.44%
Specialty Industrial Machinery
Misc Industrial & Commercial Machinery & Equipment
Link
Ireland
DUBLIN